Excellent news from India: Hydrocyn has received approval from the Central Drugs Standard Control Organization (CDSCO) to start commercialization. This achievement marks the culmination of a rigorous and lengthy approval process, underscoring the team’s commitment to meeting the stringent regulatory standards required to bring Hydrocyn to the Indian market.

The journey to obtaining CDSCO approval for Hydrocyn has been a long one. The comprehensive evaluation process, designed to ensure the safety and effectiveness of medical products in India, reflects the robustness of Hydrocyn and potential to make a significant impact.

India represents a rapidly growing healthcare market, with a burgeoning demand for advanced medical technologies and solutions, especially in the wound management market, where India offers significant opportunities for Hydrocyn. Thanks to the market’s growing demand for advanced wound care solutions, driven by a combination of factors, Bactiguard can establish a strong presence in the market.

The approval by CDSCO is a critical milestone that paves the way for future successes as we finally can explore the vast opportunities for Hydrocyn within India’s healthcare market. It is a testament to great teamwork locally and internationally to impact patient outcomes.

For further information, please contact:

Sofia Hasselgren, Global Marketing Lead Wound Management: sofia.hasselgren@bactiguard.com